company background image

Cabot NYSE:CBT Stock Report

Last Price


Market Cap







15 May, 2022


Company Financials +
CBT fundamental analysis
Snowflake Score
Future Growth4/6
Past Performance1/6
Financial Health3/6

CBT Stock Overview

Cabot Corporation operates as a specialty chemicals and performance materials company.

Cabot Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cabot
Historical stock prices
Current Share PriceUS$67.76
52 Week HighUS$74.87
52 Week LowUS$47.59
1 Month Change0.97%
3 Month Change-2.81%
1 Year Change8.80%
3 Year Change58.32%
5 Year Change31.73%
Change since IPO637.52%

Recent News & Updates

May 12

Cabot Corporation: Excellent Performance, Good Future

Cabot Corporation has outperformed comparative indexes since I wrote about the company last - some time ago. I still have a small portion of my investment. As a commodity chemicals business, Cabot is potentially slated to outperform in this environment, even with pressure from certain industries. I expect Cabot to outperform based on current macro expectations - and because of this, I'm revisiting my thesis here.

Shareholder Returns

CBTUS ChemicalsUS Market

Return vs Industry: CBT exceeded the US Chemicals industry which returned -6.2% over the past year.

Return vs Market: CBT exceeded the US Market which returned -10.4% over the past year.

Price Volatility

Is CBT's price volatile compared to industry and market?
CBT volatility
CBT Average Weekly Movement4.1%
Chemicals Industry Average Movement7.1%
Market Average Movement7.8%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: CBT is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: CBT's weekly volatility (4%) has been stable over the past year.

About the Company

18824,500Sean Keohane

Cabot Corporation operates as a specialty chemicals and performance materials company. It operates through three segments: Reinforcement Materials, Performance Chemicals, and Purification Solutions. The company offers reinforcing carbons used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites.

Cabot Fundamentals Summary

How do Cabot's earnings and revenue compare to its market cap?
CBT fundamental statistics
Market CapUS$3.83b
Earnings (TTM)US$130.00m
Revenue (TTM)US$3.88b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CBT income statement (TTM)
Cost of RevenueUS$3.05b
Gross ProfitUS$829.00m
Other ExpensesUS$699.00m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)2.30
Gross Margin21.36%
Net Profit Margin3.35%
Debt/Equity Ratio125.4%

How did CBT perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio


Is Cabot undervalued compared to its fair value and its price relative to the market?

Valuation Score


Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: CBT ($67.76) is trading below our estimate of fair value ($113.75)

Significantly Below Fair Value: CBT is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: CBT is poor value based on its PE Ratio (29.5x) compared to the US Chemicals industry average (17x).

PE vs Market: CBT is poor value based on its PE Ratio (29.5x) compared to the US market (15.5x).

Price to Earnings Growth Ratio

PEG Ratio: CBT is good value based on its PEG Ratio (0.7x)

Price to Book Ratio

PB vs Industry: CBT is overvalued based on its PB Ratio (4.2x) compared to the US Chemicals industry average (2.1x).

Future Growth

How is Cabot forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score


Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CBT's forecast earnings growth (43.6% per year) is above the savings rate (1.9%).

Earnings vs Market: CBT's earnings (43.6% per year) are forecast to grow faster than the US market (12.6% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CBT's revenue (3% per year) is forecast to grow slower than the US market (8% per year).

High Growth Revenue: CBT's revenue (3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CBT's Return on Equity is forecast to be high in 3 years time (38.8%)

Past Performance

How has Cabot performed over the past 5 years?

Past Performance Score


Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CBT has a large one-off loss of $189.0M impacting its March 31 2022 financial results.

Growing Profit Margin: CBT became profitable in the past.

Past Earnings Growth Analysis

Earnings Trend: CBT's earnings have declined by 13.7% per year over the past 5 years.

Accelerating Growth: CBT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: CBT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Chemicals industry (34.5%).

Return on Equity

High ROE: CBT's Return on Equity (15.5%) is considered low.

Financial Health

How is Cabot's financial position?

Financial Health Score


Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: CBT's short term assets ($1.8B) exceed its short term liabilities ($1.4B).

Long Term Liabilities: CBT's short term assets ($1.8B) exceed its long term liabilities ($1.1B).

Debt to Equity History and Analysis

Debt Level: CBT's net debt to equity ratio (105.3%) is considered high.

Reducing Debt: CBT's debt to equity ratio has increased from 68.4% to 125.4% over the past 5 years.

Debt Coverage: CBT's debt is not well covered by operating cash flow (9.9%).

Interest Coverage: CBT's interest payments on its debt are well covered by EBIT (14.3x coverage).

Balance Sheet


What is Cabot current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 5/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: CBT's dividend (2.18%) is higher than the bottom 25% of dividend payers in the US market (1.54%).

High Dividend: CBT's dividend (2.18%) is low compared to the top 25% of dividend payers in the US market (4.05%).

Stability and Growth of Payments

Stable Dividend: CBT's dividends per share have been stable in the past 10 years.

Growing Dividend: CBT's dividend payments have increased over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: With its reasonable payout ratio (62.8%), CBT's dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: CBT is paying a dividend but the company has no free cash flows.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Sean Keohane (54 yo)





Mr. Sean D. Keohane serves as Independent Director of The Chemours Company since May 3, 2018. He has been the Chief Executive Officer and President of Cabot Corporation since March 11, 2016. He was a membe...

CEO Compensation Analysis

Compensation vs Market: Sean's total compensation ($USD8.24M) is about average for companies of similar size in the US market ($USD6.90M).

Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: CBT's management team is seasoned and experienced (5.1 years average tenure).

Board Members

Experienced Board: CBT's board of directors are considered experienced (5.4 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Cabot Corporation's employee growth, exchange listings and data sources

Key Information

  • Name: Cabot Corporation
  • Ticker: CBT
  • Exchange: NYSE
  • Founded: 1882
  • Industry: Commodity Chemicals
  • Sector: Materials
  • Implied Market Cap: US$3.834b
  • Shares outstanding: 56.59m
  • Website:

Number of Employees


  • Cabot Corporation
  • Two Seaport Lane
  • Suite 1400
  • Boston
  • Massachusetts
  • 02210-2019
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/15 00:00
End of Day Share Price2022/05/13 00:00
Annual Earnings2021/09/30

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.